“Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Alpha-1 Antitrypsin Deficiency (AATD) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Alpha-1 Antitrypsin Deficiency and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alpha-1 Antitrypsin Deficiency market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Types
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
Immunomodulators; Serine endopeptidase inhibitors
Alpha 1 antitrypsin modulators
Alpha 1 antitrypsin inhibitors; RNA interference
Leucocyte elastase inhibitors
Alpha 1 antitrypsin modulators; RNA interference
Learn How the Ongoing Clinical & Commercial Activities will Affect the Alpha-1 Antitrypsin Deficiency Therapeutic Segment @
https://www.delveinsight.com/sample-request/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight
Alpha-1 Antitrypsin Deficiency Therapeutics Landscape
There are approx. 12+ key companies developing therapies for Alpha1-Antitrypsin Deficiency (AATD). Currently, Arrowhead Pharmaceuticals is leading the therapeutics market with its Alpha1-Antitrypsin Deficiency (AATD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Alpha-1 Antitrypsin Deficiency Therapeutics Market Include:
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Beam Therapeutics
Centessa Pharmaceuticals
CSL Behring
Grifols
Inhibrx
Kamada
Kamada Ltd
LFB Biotechnologies
Mereo Biopharma
Promethera Biosciences
Santhera Pharmaceuticals
Shire
WaVe Life Sciences
And Many Others
Alpha1-Antitrypsin Deficiency (AATD) Drugs Covered in the Report Include
ALN-AAT02: Alnylam Pharmaceuticals
Alvelestat: Mereo Biopharma)
ARO AAT: Arrowhead Pharmaceuticals
DCR-A1AT: Dicerna Pharmaceuticals, Inc.
INBRX-101: Inhibrx, Inc.
Kamada-AAT for Inhalation: Kamada, Ltd.
VX-864: Vertex Pharmaceuticals Incorporated
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns
4. Alpha-1 Antitrypsin Deficiency – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase-III)
7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)
8. Alpha-1 Antitrypsin Deficiency Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alpha-1 Antitrypsin Deficiency Discontinued Products
13. Alpha-1 Antitrypsin Deficiency Product Profiles
14. Key Companies in the Alpha-1 Antitrypsin Deficiency Market
15. Key Products in the Alpha-1 Antitrypsin Deficiency Therapeutics Segment
16. Dormant and Discontinued Products
17. Alpha-1 Antitrypsin Deficiency Unmet Needs
18. Alpha-1 Antitrypsin Deficiency Future Perspectives
19. Alpha-1 Antitrypsin Deficiency Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com
